GFM
DSGN icon

GF Fund Management’s Design Therapeutics DSGN Stock Holding History

GF Fund Management’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.5K Buy
1,271
+153
+14% +$1.55K ﹤0.01% 535
2025
Q4 		$10.5K Sell
1,118
-95
-8% -$744 ﹤0.01% 570
2025
Q3 		$9.13K Sell
1,213
-236
-16% -$1.18K ﹤0.01% 560
2025
Q2 		$4.88K Hold
1,449
– – ﹤0.01% 628
2025
Q1 		$5.59K Buy
1,449
+260
+22% +$1.24K ﹤0.01% 617
2024
Q4 		$7.34K Buy
+1,189
New +$6.88K ﹤0.01% 581

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

GF Fund Management's DSGN Position: Q1 2026 in Review

GF Fund Management increased its Design Therapeutics (DSGN) stake by 14% in Q1 2026, buying an estimated $1.55K and bringing the position to 1,271 shares worth $13.5K. The position accounts for ﹤0.01% of the portfolio, ranked #535.

GF Fund Management first reported a position in DSGN in Q4 2024 and has held it in 6 quarters since. 125 funds tracked by Wall St. Rank hold DSGN as of Q1 2026.

  • GF Fund Management held 1,271 shares of Design Therapeutics worth $13.5K as of Q1 2026.
  • GF Fund Management bought 153 Design Therapeutics shares in Q1 2026, an estimated $1.55K.
  • Design Therapeutics made up ﹤0.01% of GF Fund Management's portfolio in Q1 2026, its #535 holding.
  • GF Fund Management first reported a position in Design Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • 125 funds tracked by Wall St. Rank held Design Therapeutics as of Q1 2026.

Based on GF Fund Management's 13F filing for Q1 2026, filed 15 Apr 2026.